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  O
ne of the most famous direct-
to-consumer television adverts 
for a drug begins with a 
vibrant woman dancing late into the 
night. A background voice says, “Your 
doctor probably never sees you when 
you feel like this.” The advert cuts to 
a shrunken and glum ﬁ  gure, and the 
voiceover now says, “This is who your 
doctor usually sees.” Cutting again to 
the woman, in active shopping mode, 
clutching bags with the latest brand 
names, we hear: “That’s why so many 
people with bipolar disorder are being 
treated for depression and not getting 
any better—because depression is only 
half the story.” We see the woman again 
depressed, looking at bills that have 
arrived in the post before switching to 
seeing her again energetically painting 
her apartment. “That fast- talking, 
energetic, quick tempered, overdoing 
it, up-all-night you,” says the voiceover, 
“probably never shows up at the 
doctor’s ofﬁ  ce, right?”
    No drugs are mentioned. But 
viewers are encouraged to log onto 
www.bipolarawareness.com, which 
takes them to a Web site called 
“Bipolar Help Center,” sponsored 
by Lilly Pharmaceuticals, the makers 
of olanzapine (Zyprexa). The Web 
site contains a “mood disorder 
questionnaire” (http:⁄⁄www.
bipolarhelpcenter.com/resources/
mdq.jsp). In the television advert, we 
see our heroine logging onto www.
bipolarawareness.com and ﬁ  nding this 
questionnaire. The voice encourages 
the viewer to follow her example: “Take 
the test you can take to your doctor, it 
can change your life….getting a correct 
diagnosis is the ﬁ  rst step in treating 
bipolar disorder. Help your doctor to 
help you.”
    This advert markets bipolar disorder. 
The advert can be read as a genuine 
attempt to alert people who may 
be suffering from one of the most 
debilitating and serious psychiatric 
diseases—manic-depressive illness. 
Alternatively, the advert can be read as 
an example of what has been termed 
disease mongering [1]. Whichever it 
is, it will reach beyond those suffering 
from a mood disorder to others who will 
as a consequence be more likely to see 
aspects of their personal experiences 
in a new way that will lead to medical 
consultations and in a way that will shape 
the outcome of those consultations. 
Adverts that encourage “mood 
watching” risk transforming variations 
from an emotional even keel into 
potential indicators of latent or actual 
bipolar disorder. This advert appeared 
in 2002 shortly after Lilly’s antipsychotic 
olanzapine had received a license for 
treating mania. The company was also 
running trials aimed at establishing 
olanzapine as a “mood stabilizer,” one of 
which was recently published [2].  
  Mood  Stabilization
    From the 1950s on, the depressions 
of manic-depressive illness have been 
treated with antidepressants and the 
manias with antipsychotics or lithium. 
Lithium was the only agent thought 
to be prophylactic against further 
episodes of manic-depressive illness 
[3]. But lithium was not originally 
referred to as a mood stabilizer. The 
term “mood stabilizer” had barely 
been heard of before 1995 when 
Abbott Laboratories got a license 
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for using the anticonvulsant sodium 
valproate (Depakote) for treating 
acute mania [4]. 
    After 1995, there was a dramatic 
growth in the frequency with which 
the term “mood stabilizer” appeared 
in the title of scientiﬁ  c articles (see 
Figure 1). By 2001, more than a 
hundred article titles a year featured 
this term. Repeated reviews make it 
clear that the academic psychiatric 
community still has not come to a 
consensus on what the term “mood 
stabilizer” means [5–7]. But this lack 
of consensus did not get in the way of 
the message that patients with bipolar 
disorders needed to be detected 
and once detected needed mood 
stabilizers, and perhaps should only be 
given these drugs and not any other 
psychotropic drugs [8,9]. 
    The ﬁ  rst group of drugs to colonize 
this new mood stabilizer niche was 
anticonvulsants. Anticonvulsants are 
beneﬁ  cial in epilepsy and were until 
recently widely thought to be beneﬁ  cial 
by quenching the increased risk of 
succeeding epileptic ﬁ  ts brought 
about by ﬁ  ts that have gone before. 
Robert Post in the 1980s suggested 
that anticonvulsants might stabilize 
moods by a comparable quenching 
of the kindling effect of an episode of 
mood disorders on the risk of further 
episodes [10]. It was this idea that 
provided a pharmacological rationale 
for treatment of bipolar disorders that 
was so attractive to pharmaceutical 
companies, and, in their hands, 
the growth of awareness of mood 
stabilization and of bipolar disorders 
was sensational.  
    Bipolar disorders entered the DSM 
  (Diagnostic and Statistical Manual of 
Mental Disorders)   in 1980. At the time, 
the criteria for bipolar I disorder 
(classic manic-depressive illness) 
involved an episode of hospitalization 
for mania. Since then, the community-
based disorders bipolar II disorder, 
bipolar disorders NOS (not otherwise 
speciﬁ  ed), and cyclothymia have 
emerged. With their emergence, 
estimates for the prevalence of bipolar 
disorders have risen from 0.1% of 
the population having bipolar I 
disorder (involving an episode of 
hospitalization for mania) [11] to 5% 
or more when the deﬁ  nition of bipolar 
disorders includes the aforementioned 
community disorders [12]. A range of 
academic institutions has also grown 
more interested in the condition.   
    There has always been a rationale 
to using antipsychotics in bipolar 
disorders, as they are effective in 
acute manic states [13,14]. However, 
no companies making antipsychotics 
had previously sought a license 
for   prophylaxis   against bipolar 
disorders. Against a background of 
epidemiological studies indicating that 
the prevalence of bipolar disorders 
might be greater than previously 
thought [15,16], and growing academic 
interest in the condition, Lilly, Janssen, 
and Astra-Zeneca, the makers of the 
antipsychotics olanzapine, risperidone, 
and quetiapine (Seroquel), 
respectively, marched in on the new 
territory to market these drugs for 
prophylaxis of bipolar disorder. This, in 
turn, greatly expanded the number of 
companies with an interest in making 
the “bipolar market.” There was, 
however, no consensus on a theoretical 
rationale that would lead the average 
clinician to think these three drugs 
might “quench” the propensity to 
further affective episodes, as opposed 
to simply assist in the management of 
acute manic states. 
    But the increased prevalence 
estimates were based on community 
surveys that had no clear disability 
criterion, while acute treatment 
trials of antipsychotics for mania, 
and prophylactic trials of lithium for 
manic-depressive illness, have for the 
most part been conducted on bipolar 
I disorder. This necessarily raises the 
prospect that increased efforts to detect 
and to treat people risks crossing the 
line where the beneﬁ  ts of treatment 
outweigh its risks.
    Along with this expansion in 
prevalence estimates came new 
journals,   Bipolar Disorders   (http:⁄⁄www.
blackwellpublishing.com/journal.
asp?ref=1398-5647) and the   Journal 
of Bipolar Disorders   (published by 
Lippincott, Williams, and Wilkins), a 
slew of bipolar societies, and annual 
conferences, many heavily funded by 
pharmaceutical companies. There 
is a growing amount of patient Web 
site and patient support materials 
that in the case of Zyprexa state that 
“bipolar disorder is often a lifelong 
illness needing lifelong treatment; 
symptoms come and go, but the illness 
stays; people feel better because the 
medication is working; almost everyone 
who stops taking the medication will 
get ill again and the more episodes 
you have, the more difﬁ  cult they are to 
treat” [17]. Information available from 
Janssen (the makers of Risperdal) states 
“medicines are crucially important in 
the treatment of bipolar disorders. 
Studies over the past twenty years 
have shown beyond the shadow of 
doubt that people who receive the 
appropriate drugs are better off in the 
long term than those who receive no 
medicine” [18]. 
  What  Lies  Beneath 
    There is, however, much less evidence 
than many might think to support 
these claims for the prophylactic drug 
treatment of manic-depressive illness 
(bipolar I). And there is almost no 
evidence to support such claims in the 
case of whatever community disorders 
(bipolar II, bipolar NOS, cyclothymia) 
are now being pulled into the manic-
depressive net by the lure of bipolar 
disorder.  
    With the possible exception of 
lithium for bipolar I disorder, there 
are no randomized controlled trials 
to show that patients with bipolar 
disorders in general who receive 
psychotropic drugs are better in the 
long term than those who receive no 
medicine [19]. This may stem in part 
from difﬁ  culties in conducting trials 
on psychotropic drugs that last more 
than a few weeks in conditions as 
complex as manic-depressive illness. 
One short-term, randomized, placebo-
controlled trial (in which patients were 
only followed for up to 48 weeks) that 
some see as a basis for claiming that 
olanzapine may be prophylactic in 
bipolar disorder [2] has been regarded 
by others as indicating that this drug 
produces a withdrawal-induced 
decompensation when stopped [20]. 
Even in the case of lithium, there 
is some dispute over what has been 
demonstrated [19], with the best 
evidence stemming from large open 
studies in dedicated lithium services 
rather than from randomized trials 
[21]. 
    This evidence of beneﬁ  t for 
one agent (lithium) and possible 
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beneﬁ  t for one more (olanzapine) 
must be weighed against two harms 
associated with use of antipsychotics: 
(1) a consistent body of evidence 
indicates that regular treatment with 
antipsychotics in the longer run 
increases mortality [22–26]; and (2) 
there is evidence that in placebo-
controlled trials of antipsychotics 
submitted in application for 
schizophrenia licenses there is a 
statistically signiﬁ  cant excess of 
completed suicides on active treatment 
[27]. A range of problems associated 
with antipsychotics, from increased 
mortality to tardive dyskinesia, never 
show up in the short-term trials aimed 
at demonstrating treatment effects in 
psychiatry.  
    But aside from these hazards, there 
are also grounds to question whether 
the treatment effects that some think 
have been demonstrated in bipolar 
disorder trials translate into therapeutic 
efﬁ  cacy. If use of these agents based 
on demonstrated effects leads on 
to efﬁ  cacy, admissions for bipolar 
disorder might be expected to fall, 
but the evidence for this is difﬁ  cult 
to ﬁ  nd. In North Wales before the 
advent of modern pharmacotherapy, 
patients with bipolar I disorder had 
on average four admissions every ten 
years. In contrast, against a background 
of a constant incidence of bipolar I 
disorder, and dramatic improvements 
in service provision, bipolar I patients 
show a 4-fold increase in the prevalence 
of admissions despite being treated 
with the very latest psychotropic 
medications [11]. This is not ordinarily 
what happens when treatments “work,” 
but quite often is what happens when 
treatments have effects.
    The selling of bipolar disorder 
stresses that the disorder takes 
a fearsome toll of suicides. And 
indeed the controversy surrounding 
the provocation of suicide by 
antidepressants has been recast by 
some as a consequence of mistaken 
diagnosis. If the treating physician 
had only realized the patient was 
bipolar, they would not have mistakenly 
prescribed an antidepressant. Because 
of the suicide risk traditionally linked 
to patients with bipolar disorders 
who needed hospitalisation, most 
psychiatrists would ﬁ  nd it difﬁ  cult 
to leave any person with a case of 
bipolar disorder unmedicated. Yet, 
the best available evidence shows that 
unmedicated patients with bipolar 
disorder do   not   have a higher risk of 
suicide.  
    Storosum and colleagues analyzed 
all placebo-controlled, double-blind, 
randomized trials of mood stabilizers 
for the prevention of manic/depressive 
episode that were part of a registration 
dossier submitted to the regulatory 
authority of the Netherlands, the 
Medicines Evaluation Board, between 
1997 and 2003 [28]. They found four 
such prophylaxis trials. They compared 
suicide risk in patients on placebo 
compared with patients on active 
medication. Two suicides (493/100,000 
person- years of exposure) and eight 
suicide attempts (1,969/100,000 
person-years of exposure) occurred 
in the group given an active drug 
(943 patients), but no suicides and 
two suicide attempts (1,467/100,000 
person-years of exposure) occurred 
in the placebo group (418 patients). 
Based on these absolute numbers from 
these four trials, I have calculated (see 
Figure S1 showing calculation, and 
see Figure 2) that active agents are 
most likely to be associated with a 2.22 
times greater risk of suicidal acts than 
placebo (95% CI 0.5, 10.00).
  The  Bipolar  Future
    Until recently the general clinical 
wisdom was that it was very rare for 
manic-depressive illness to have an 
onset in the preteen years. But there 
is now a surge of diagnoses of bipolar 
disorder in American children [29,30], 
even though these children do not 
meet the traditional criteria for bipolar 
I disorder (from the   Diagnostic and 
Statistical Manual of Mental Disorders  ) 
[31]. The mania for pediatric bipolar 
disorder hit the front cover of the 
American edition of   Time   in August 
2002, which featured nine-year-old 
Ian Palmer and a cover title   Young and 
Bipolar  , with a strapline,   why are so many 
kids being diagnosed with the disorder, once 
known as manic-depression? 
    A recent book,   The Bipolar Child   
[32], brings out the extent of the 
current mania. Published in 2000, 
this book sold 70,000 hardback 
copies in six months in the US. As the 
  Star Telegram   reported in July 2000 
[33],   The Bipolar Child   made all the 
difference to Heather Norris, whose 
mother, after reading it, challenged 
her physician to correct Heather’s 
diagnosis from ADHD, treatment of 
which had made her daughter worse, 
to the correct diagnosis of bipolar 
disorder. As a result, Heather, at the 
age of two, became the youngest child 
in Tarrant County, Texas, to have a 
diagnosis of bipolar disorder. The   Star 
Telegram   article noted that “along with 
the insurance woes, lack of treatment 
options and weak support systems that 
plague most families with mentally ill 
children, parents of the very young 
face additional challenges. Finding 
the proper diagnosis for treatment is 
a nightmare because of scant research 
into childhood mental illness and the 
drugs that combat them.”  
    If we consider adults alone for a 
moment, there is already the potential 
for creating an “epidemic” of bipolar 
disorder, because people are being 
diagnosed with the condition based on 
operational criteria that depend upon 
subjective judgements (rather than an 
objective criterion of disability, such as 
hospitalization or being off work for a 
month). The potential is compounded 
in the pediatric domain by the fact 
that the diagnosis is based on caregiver 
reports with little scope in most clinical 
practice for critical scrutiny of the 
social forces that may lead to these 
reports. Experts that appear willing 
to go so far as to accept the possibility 
that the ﬁ  rst signs of bipolar disorder 
may be patterns of overactivity in 
utero [32] can only further compound 
these problems. If the resulting 
diagnoses were provisional, aimed 
at researching the natural history of 
childhood irritability, rather than 
reaching diagnoses that lead on to 
pharmacotherapy, there might be 
little problem. However, drugs such as 
Zyprexa and Risperdal are now being 
used for preschoolers in America with 
little questioning of this development 
[31]. 
    Far from research bringing a 
skeptical note to bear on clinical 
DOI: 10.1371/journal.pmed.0030185.g002 
  Figure 2.   Author’s Graph of     p  -Value 
Function Based on Data in [30]
   (Illustration:  Sapna  Khandwala)   
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enthusiasm, it appears to be adding 
fuel to the ﬁ  re. What might once have 
been thought of as sober institutions, 
such as Massachusetts General 
Hospital, have run trials of Risperdal 
and Zyprexa on children with a 
mean age of four years old [34,35]. 
Massachusetts General Hospital in fact 
recruited trial participants by running 
its own television adverts featuring 
clinicians and parents alerting parents 
to the fact that difﬁ  cult and aggressive 
behavior in children aged four and 
up might stem from bipolar disorder. 
This does more than recruit patients 
with a clear disorder; it suggests that 
everyday behavioral difﬁ  culties may 
be better seen in terms of a disorder. 
Given that bipolar disorder in children 
is all but unrecognised outside the 
US, it seems likely that a signiﬁ  cant 
proportion of these children will not 
meet conventional DSM criteria for 
bipolar I disorder. And given that it is 
all but impossible for a short-term trial 
of sedative agents in pediatric states 
characterized by overactivity   not   to show 
some rating scale changes that can be 
regarded as beneﬁ  cial, the outcomes 
of this research are likely to appear to 
validate the diagnosis and increase the 
pressure for treatment.   
    Several years after Heather Norris 
was diagnosed with bipolar disorder, 
the rationale for mood stabilization 
was greatly weakened by the results 
of the largest-ever randomized 
trial of immediate versus deferred 
anticonvulsant therapy for people 
who had experienced a single seizure 
[36]. The trial found that although 
immediate antiepileptic drug 
treatment reduces the occurrence 
of seizures in the next 1–2 years, 
such treatment does not affect long-
term remission in individuals with 
single or infrequent seizures. The 
use of psychotropic medication for 
bipolar disorders was based on an 
analogy with epilepsy, rather than 
on demonstrations of proven clinical 
beneﬁ  ts over the long term or on 
the basis of a correction of a known 
pathophysiology. The absence of a 
solid theoretical or empirical basis 
for using psychotropic medication as 
“mood stabilizers” raises questions as 
to what lies in store for the Heather 
Norris’s and others of this world 
exposed to these complex psychotropic 
agents from such a young age.   
  Supporting  Information
      Figure S1.   Episheet Showing Author’s 
Relative Risk Calculation, Based on Data in 
[30] 
    Found at DOI: 10.1371/journal.
pmed.0030185.sg001 (792 KB XLS). 
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